Developing anti-CD19 antibody-based combinations in lymphoma

被引：2
|
作者：
Kuruvilla, John [1 ]
机构：
[1] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada
来源：
LANCET ONCOLOGY | 2020年 / 21卷 / 07期
关键词：
D O I：
10.1016/S1470-2045(20)30275-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：870 / 872
页数：3
相关论文
共 50 条
  • [21] The therapeutic effect of anti-CD19 antibody on DHEA-induced PCOS mice
    Wang, Ting
    Xiong, Xingliang
    Xiao, Na
    Yan, Yizhong
    Liu, Xiaoyang
    Xie, Qi
    Su, Xian
    Chen, Maosheng
    Peng, Jing
    Wang, Siqi
    Mei, Hua
    Lin, Ge
    Gong, Fei
    Cheng, Lamei
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 130
  • [22] The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma
    Flavell, DJ
    Warnes, SL
    Bryson, CJ
    Field, SA
    Noss, AL
    Packham, G
    Flavell, SU
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 134 (02) : 157 - 170
  • [23] B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody
    Herbst, Ronald
    Wang, Yue
    Gallagher, Sandra
    Mittereder, Nanette
    Kuta, Ellen
    Damschroder, Melissa
    Woods, Rob
    Rowe, Daniel C.
    Cheng, Li
    Cook, Kim
    Evans, Krista
    Sims, Gary P.
    Pfarr, David S.
    Bowen, Michael A.
    Dall'Aqua, William
    Shlomchik, Mark
    Tedder, Thomas F.
    Kiener, Peter
    Jallal, Bahija
    Wu, Herren
    Coyle, Anthony J.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 335 (01): : 213 - 222
  • [24] ANTI-CD19 STRATEGIES IN HEMATOLOGICAL MALIGNANCIES
    Leslie, L.
    Younes, A.
    DRUGS OF THE FUTURE, 2013, 38 (12) : 835 - 843
  • [25] A signal sequence trap based on cell enrichment using Anti-CD19 antibody coated magnetic beads
    Rian, E
    Wabakken, T
    Hauge, H
    Aasheim, HC
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2001, 54 (03) : 280 - 284
  • [26] The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine Achieved Responses in Patients with Diffuse Large B-Cell Lymphoma Who Relapsed after Anti-CD19 CAR T-Cell Therapy
    Caimi, Paolo F.
    Ardeshna, Kirit M.
    Reid, Erin
    Ai, Weiyun Z.
    Lunning, Matthew A.
    Zain, Jasmine
    Solh, Melhem
    Kahl, Brad S.
    Hamadani, Mehdi
    BLOOD, 2021, 138
  • [27] Characterization of porcine CD19 and anti-CD19 monoclonal antibodies
    Sun, JS
    Sinkora, J
    Wertz, N
    Moravkova, A
    Butler, JE
    MOLECULAR IMMUNOLOGY, 2004, 41 (09) : 929 - 938
  • [28] Conjugation of blocked ricin to an anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD19 internalization
    Goulet, AC
    Goldmacher, VS
    Lambert, JM
    Baron, C
    Roy, DC
    Kouassi, E
    BLOOD, 1997, 90 (06) : 2364 - 2375
  • [29] Pharmacological profile of MEDI-551, a novel anti-CD19 antibody, in human CD19 transgenic mice
    Gallagher, Sandra
    Turman, Sean
    Yusuf, Isharat
    Akhgar, Ahmad
    Wu, Yuling
    Roskos, Lorin K.
    Herbst, Ronald
    Wang, Yue
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2016, 36 : 205 - 212
  • [30] Sequencing of Anti-CD19 Therapies in the Management of Diffuse Large B-Cell Lymphoma
    Lownik, Joseph
    Boiarsky, Jonathan
    Birhiray, Ruemu
    Merchant, Akil
    Mead, Monica
    CLINICAL CANCER RESEARCH, 2024, 30 (14) : 2895 - 2904
12345